BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36812891)

  • 21. High expression of IDO1 and TGF-β1 during recurrence and post infection clearance with Chlamydia trachomatis, are independent of host IFN-γ response.
    Ziklo N; Huston WM; Taing K; Timms P
    BMC Infect Dis; 2019 Mar; 19(1):218. PubMed ID: 30832593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
    Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
    J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation.
    Zhong W; Gao L; Zhou Z; Lin H; Chen C; Huang P; Huang W; Zhou C; Huang S; Nie L; Liu Y; Chen Y; Zhou D; Lv Z
    Oncotarget; 2017 Jun; 8(25):40486-40500. PubMed ID: 28465467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IDO1 Signaling through GCN2 in a Subpopulation of Gr-1
    Dey S; Mondal A; DuHadaway JB; Sutanto-Ward E; Laury-Kleintop LD; Thomas S; Prendergast GC; Mandik-Nayak L; Muller AJ
    Cancer Immunol Res; 2021 May; 9(5):514-528. PubMed ID: 33622713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon γ gene transfer on interferon γ-mediated antitumor activity.
    Watcharanurak K; Zang L; Nishikawa M; Yoshinaga K; Yamamoto Y; Takahashi Y; Ando M; Saito K; Watanabe Y; Takakura Y
    Gene Ther; 2014 Sep; 21(9):794-801. PubMed ID: 24919418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tryptophan catabolism is dysregulated in leiomyomas.
    Chuang TD; Quintanilla D; Boos D; Khorram O
    Fertil Steril; 2021 Oct; 116(4):1160-1171. PubMed ID: 34116832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter.
    Rovira Gonzalez YI; Lynch PJ; Thompson EE; Stultz BG; Hursh DA
    Cytotherapy; 2016 Sep; 18(9):1114-28. PubMed ID: 27421739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma.
    Li S; Han X; Lyu N; Xie Q; Deng H; Mu L; Pan T; Huang X; Wang X; Shi Y; Zhao M
    Cancer Sci; 2018 Dec; 109(12):3726-3736. PubMed ID: 30264546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration.
    Liu XQ; Lu K; Feng LL; Ding M; Gao JM; Ge XL; Wang X
    Leuk Lymphoma; 2014 Feb; 55(2):405-14. PubMed ID: 23682557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature.
    Sailer V; Sailer U; Bawden EG; Zarbl R; Wiek C; Vogt TJ; Dietrich J; Loick S; Grünwald I; Toma M; Golletz C; Gerstner A; Kristiansen G; Bootz F; Scheckenbach K; Landsberg J; Dietrich D
    EBioMedicine; 2019 Oct; 48():341-352. PubMed ID: 31628024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.
    Thaker AI; Rao MS; Bishnupuri KS; Kerr TA; Foster L; Marinshaw JM; Newberry RD; Stenson WF; Ciorba MA
    Gastroenterology; 2013 Aug; 145(2):416-25.e1-4. PubMed ID: 23669411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
    Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
    Front Immunol; 2021; 12():800630. PubMed ID: 35003126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
    Gostner JM; Becker K; Überall F; Fuchs D
    Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.
    Opitz CA; Litzenburger UM; Opitz U; Sahm F; Ochs K; Lutz C; Wick W; Platten M
    PLoS One; 2011; 6(5):e19823. PubMed ID: 21625531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1.
    Liang F; Wang GZ; Wang Y; Yang YN; Wen ZS; Chen DN; Fang WF; Zhang B; Yang L; Zhang C; Han SC; Yang FY; Wang D; Liang LJ; Wang Z; Zhao Y; Wang CL; Zhang L; Zhou GB
    Signal Transduct Target Ther; 2022 Sep; 7(1):311. PubMed ID: 36068203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different effects of tryptophan 2,3-dioxygenase inhibition on SK-Mel-28 and HCT-8 cancer cell lines.
    Paccosi S; Cecchi M; Silvano A; Fabbri S; Parenti A
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3155-3163. PubMed ID: 32776284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-γ converts human microvascular pericytes into negative regulators of alloimmunity through induction of indoleamine 2,3-dioxygenase 1.
    Liu R; Merola J; Manes TD; Qin L; Tietjen GT; López-Giráldez F; Broecker V; Fang C; Xie C; Chen PM; Kirkiles-Smith NC; Jane-Wit D; Pober JS
    JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer.
    Tsai YS; Jou YC; Tsai HT; Cheong IS; Tzai TS
    Urol Oncol; 2019 Nov; 37(11):810.e17-810.e27. PubMed ID: 31253481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
    Liu X; Shin N; Koblish HK; Yang G; Wang Q; Wang K; Leffet L; Hansbury MJ; Thomas B; Rupar M; Waeltz P; Bowman KJ; Polam P; Sparks RB; Yue EW; Li Y; Wynn R; Fridman JS; Burn TC; Combs AP; Newton RC; Scherle PA
    Blood; 2010 Apr; 115(17):3520-30. PubMed ID: 20197554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.